Cobicistat(continued)
▶Cobicistatis predicted to increase the exposure toretinoids
(alitretinoin). Adjustalitretinoindose.oTheoretical
▶Cobicistatis predicted to increase the exposure toribociclib.
Avoid or adjustribociclibdose.oStudy
▶Rifabutindecreases the concentration ofcobicistatand
cobicistatincreases the exposure torifabutin. Avoid or adjust
dose.rStudy
▶Rifampicinis predicted to decrease the exposure tocobicistat.
Avoid.rTheoretical
▶Cobicistatis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Cobicistatis predicted to increase the exposure toruxolitinib.
Adjust dose and monitor side effects.oStudy
▶Cobicistatis predicted to increase the exposure tosaxagliptin.
oStudy
▶Cobicistatis predicted to increase the exposure tosimeprevir.
Avoid.rStudy
▶Cobicistatis predicted to increase the concentration of
sirolimus. Avoid.rStudy
▶Cobicistatis predicted to increase the exposure tosolifenacin.
Adjustsolifenacinortamsulosin with solifenacindose; avoid in
hepatic and renal impairment.rStudy
▶Cobicistatis predicted to moderately increase the exposure to
SSRIs(dapoxetine). Avoid potent inhibitors of CYP3A4 or
adjustdapoxetinedose.rStudy
▶St John’s Wortis predicted to decrease the exposure to
cobicistat. Avoid.rTheoretical
▶Cobicistatis predicted to increase the exposure tostatins
(atorvastatin). Avoid or adjust dose and monitor
rhabdomyolysis.rStudy
▶Cobicistatis predicted to increase the exposure tostatins
(simvastatin). Avoid.rStudy
▶Cobicistatis predicted to slightly increase the exposure to
sunitinib. Avoid or adjustsunitinibdose.oStudy
▶Cobicistatis predicted to increase the concentration of
tacrolimus. Monitor and adjust dose.rStudy
▶Cobicistatis predicted to increase the exposure totaxanes
(cabazitaxel). Avoid.rStudy
▶Cobicistatis predicted to moderately increase the exposure to
taxanes(docetaxel). Avoid or adjust dose.rStudy
▶Cobicistatis predicted to increase the exposure totaxanes
(paclitaxel).rTheoretical
▶Cobicistatis predicted to increase the concentration of
temsirolimus. Avoid.rTheoretical
▶Cobicistatis predicted to markedly increase the exposure to
ticagrelor. Avoid.rStudy
▶Cobicistatis predicted to increase the exposure totofacitinib.
Adjusttofacitinibdose.oStudy
▶Cobicistatis predicted to increase the exposure totolterodine.
Avoid.rStudy
▶Cobicistatis predicted to increase the exposure totolvaptan.
Adjust dose.rStudy
▶Cobicistatis predicted to increase the exposure totoremifene.
oTheoretical
▶Cobicistatis predicted to increase the exposure totrabectedin.
Avoid or adjust dose.rTheoretical
▶Cobicistatis predicted to moderately increase the exposure to
trazodone. Avoid or adjust dose.oStudy
▶Cobicistatis predicted to slightly increase the exposure to
tricyclic antidepressants.nStudy
▶Cobicistatis predicted to increase the exposure toulipristal.
Avoid if used for uterinefibroids.rStudy
▶Cobicistatis predicted to increase the exposure to
vemurafenib.rTheoretical
▶Cobicistatis predicted to increase the exposure tovenetoclax.
Avoid potent inhibitors of CYP3A4 or adjustvenetoclaxdose.
rStudy
▶Cobicistatis predicted to increase the exposure tovenlafaxine.
oStudy
▶Cobicistatis predicted to increase the exposure tovinca
alkaloids.rTheoretical
▶Cobicistatis predicted to increase the exposure tovitamin D
substances(paricalcitol).oStudy▶Cobicistatis predicted to increase the exposure tozopiclone.
Adjust dose.oTheoretical
Cobimetinib
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tocobimetinib.rTheoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tocobimetinib. Avoid.rTheoretical
▶Antifungals, azoles(fluconazole, isavuconazole, miconazole,
posaconazole)are predicted to increase the exposure to
cobimetinib.rTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to markedly increase the exposure tocobimetinib.
Avoid or monitor for toxicity.rStudy
▶Aprepitantis predicted to increase the exposure to
cobimetinib.rTheoretical
▶Bosentanis predicted to decrease the exposure tocobimetinib.
Avoid.rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocobimetinib.rTheoretical
▶Cobicistatis predicted to markedly increase the exposure to
cobimetinib. Avoid or monitor for toxicity.rStudy
▶Crizotinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Efavirenzis predicted to decrease the exposure tocobimetinib.
Avoid.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
cobimetinib. Avoid.rTheoretical
▶Grapefruit juiceis predicted to increase the exposure to
cobimetinib. Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to markedly increase the
exposure tocobimetinib. Avoid or monitor for toxicity.r
Study
▶Idelalisibis predicted to markedly increase the exposure to
cobimetinib. Avoid or monitor for toxicity.rStudy
▶Imatinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Macrolides(clarithromycin)are predicted to markedly increase
the exposure tocobimetinib. Avoid or monitor for toxicity.
rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tocobimetinib.rTheoretical
▶Mitotaneis predicted to decrease the exposure tocobimetinib.
Avoid.rTheoretical
▶Netupitantis predicted to increase the exposure to
cobimetinib.rTheoretical
▶Nevirapineis predicted to decrease the exposure to
cobimetinib. Avoid.rTheoretical
▶Nilotinibis predicted to increase the exposure tocobimetinib.
rTheoretical
▶Rifampicinis predicted to decrease the exposure to
cobimetinib. Avoid.rTheoretical
▶St John’s Wortis predicted to decrease the exposure to
cobimetinib. Avoid.rTheoretical
Codeine→see opioids
Colchicine
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tocolchicine. Adjustcolchicinedose with moderate
inhibitors of CYP3A4.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tocolchicine. Adjust
colchicinedose with moderate inhibitors of CYP3A4.r
Study
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tocolchicine. Avoid potent
inhibitors of CYP3A4 or adjustcolchicinedose.rStudy
▶Aprepitantis predicted to increase the exposure tocolchicine.
Adjustcolchicinedose with moderate inhibitors of CYP3A4.
rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocolchicine. Adjustcolchicinedose
with moderate inhibitors of CYP3A4.rStudy
▶Ceritinibis predicted to increase the exposure tocolchicine.
oTheoretical900 Cobicistat—Colchicine BNFC 2018 – 2019
Interactions|Appendix 1A1